Lifileucel

Iovance Biotherapeutics has announced five-year results from the Phase 2 C-144-01 trial showing that one-time treatment with Amtagvi (lifileucel) achieved a 20% survival rate in advanced melanoma patients previously treated with checkpoint inhibitors.

GT Biopharma has successfully completed dosing in the first cohort of its Phase 1 trial for GTB-3650, a second-generation TriKE immunotherapy, with no safety or tolerability issues observed.

NIH researchers report that a new form of tumor infiltrating lymphocyte (TIL) therapy combined with pembrolizumab achieved 23.5% objective response rate in patients with metastatic gastrointestinal cancers, compared to 7.7% with selected TILs alone.

Iovance Biotherapeutics granted inducement stock options covering 297,600 shares to fifty new employees on April 17, 2025, following similar grants of 308,710 shares to forty-three employees in March.

Iterum Therapeutics receives FDA approval for ORLYNVAH™, marking the first branded uncomplicated UTI treatment to enter the U.S. market in over 25 years and the first oral penem antibiotic approved in the country.